Skip to main
VALN
VALN logo

Valneva SE (VALN) Stock Forecast & Price Target

Valneva SE (VALN) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Valneva SE is positioned favorably due to an increased commercial uptake assumption for its vaccine candidate VLA15 in Europe, aligning it closer to expectations in the United States. The company's recent report of strong immune responses following a third booster dose of VLA15 in both adults and children further bolsters confidence in its pipeline. Despite the unexpected suspension of the Ixchiq vaccine by the FDA, the overall revenue generation from commercialized vaccines and ongoing vaccine development programs supports a positive outlook for future cash flows.

Bears say

Valneva faces significant challenges that contribute to a negative outlook, primarily due to clinical and regulatory risks that could hinder its vaccine development efforts. Recent safety concerns surrounding its Ixchiq vaccine, despite claims of superior long-term protection, could reduce its competitiveness compared to rivals such as Bavarian Nordic’s chikungunya vaccine. Additionally, the removal of US Ixchiq sales from projections, coupled with anticipated limited commercial uptake in Europe, signals a potential decline in revenue generation which could adversely impact the company’s financial standing.

Valneva SE (VALN) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Valneva SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Valneva SE (VALN) Forecast

Analysts have given Valneva SE (VALN) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Valneva SE (VALN) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Valneva SE (VALN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.